A phase III, double-blinded, randomized, multicenter, clinical study to assess the safety and immunogenicity of GSK Bio's Tdap 0.3 mg candidate vaccine when given as a booster dose to healthy school children and adolescents (9-13 years of age), previously vaccinated with a 5th consecutive dose of acellular pertussis-containing vaccine, in studies APV-118 or APV-120
Latest Information Update: 23 Aug 2023
Price :
$35 *
At a glance
- Drugs DTaP vaccine (Primary)
- Indications Diphtheria; Pertussis; Tetanus
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 03 Nov 2006 New trial record.